RxDoctor Payments Data

Ericka Taylor-Daniel, APRN

Psychiatric/Mental Health · Dover, DENPI 1992186142

Payments from drug & device makers

What this record shows

This record is dominated by speaking fees: $25,500 of the $39,481 with a category attached, or 64.6%. AbbVie accounts for 86.6% of it on its own, with 27 other manufacturers making up the rest. Reporting peaked in 2023 at $22,498 and has fallen 69.2% since, to $6,932 in 2025. Among psychiatric/mental health clinicians in DE with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$39,481in general payments, 2019–2025

Across 327 payments — averaging $120.74 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$34K
  • Johnson & Johnson$795
  • Otsuka America Pharmaceutical, Inc.$759
  • Neurocrine Biosciences, Inc.$700
  • Teva Pharmaceuticals USA, Inc.$672
  • Lundbeck LLC$463
  • plus $2K from 22 others

What the payments were for

  • Consulting fees$1,8805%
  • Speaking & faculty fees$25,50065%
  • Travel & lodging$4,84612%
  • Food & beverage$7,09718%
  • Education$1580%

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$39,481 in reported general payments places this provider in the 95th percentile of 177 psychiatric/mental health providers in Delaware.

See all psychiatric/mental health providers in Delaware

Medicare billing

Part B allowed, 2024
$9,517
Medicare patients
24
Services billed
102

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Bydureon BciseExenatide Microspheres11$9,156
Aripiprazole15$3,814
Lurasidone Hcl13$1,651
Fluoxetine Hcl78$1,472
Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl15$1,020
Trazodone Hcl19$385
Risperidone21$378
Dextroamphetamine-AmphetamineDextroamphetamine/Amphetamine15$363
Bupropion XlBupropion Hcl19$331
Ziprasidone Hcl11$237
Bupropion Hcl SrBupropion Hcl14$221
Hydroxyzine Pamoate15$85
Propranolol Hcl11$61

Paid to pharmacies, not to this prescriber.

Other psychiatric/mental health in Dover

See the full list for Delaware

Where these figures come from

Is this you, or does something look wrong? →